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OBJECTIVES Estimate the effect of angiotensin converting enzyme (ACE) inhibitors on the risk of sudden
cardiac death (SCD) following myocardial infarction (MI).
BACKGROUND Trials in post-MI patients have shown that ACE inhibitor therapy reduces mortality.
However, the effect on SCD as a mechanism has not been clarified.
METHODS Trials of ACE inhibitor therapy following MI reported between January, 1978 and August,
1997 were identified. Studies were included if they met the following criteria: 1) randomized
comparison of ACE inhibitor to placebo within 14 days of MI; 2) study duration/blinded
follow-up of $6 weeks; 3) the number of deaths and modes of death were reported or could
be obtained from the investigators.
RESULTS We identified 374 candidate articles, of which 15 met the inclusion criteria. The 15 trials
included 15,104 patients, 2,356 of whom died. Most (87%) fatalities were cardiovascular and
900 were SCDs. A significant reduction in SCD risk or a trend towards this was observed in
all of the larger (N . 500) trials. Overall, ACE inhibitor therapy resulted in significant
reductions in risk of death (random effects odds ratio [OR] 5 0.83; 95% confidence interval
[CI] 0.71–0.97), cardiovascular death (OR 5 0.82; 95% CI 0.69–0.97) and SCD (OR 5
0.80; 95% CI 0.70–0.92).
CONCLUSIONS This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk
of death following a recent MI by reducing cardiovascular mortality. Moreover, this analysis
suggests that a reduction in SCD risk with ACE inhibitors is an important component of this
survival benefit. (J Am Coll Cardiol 1999;33:598–604) © 1999 by the American College of
Cardiology
Following an acute myocardial infarction, patients are at
significantly increased risk of cardiovascular death and
nonfatal reinfarction (1). Reduced left ventricular function
and dilatation that result from the infarction and the
subsequent ventricular remodeling process are important
components of this enhanced risk (2–4). Sudden cardiac
death (SCD) accounts for about half of the deaths in these
patients (1). The propensity to fatal arrhythmias is increased
by structural changes and the degree of left ventricular
dysfunction. Neurohumoral activation, which occurs fol-
lowing acute myocardial infarction, may also be arrhythmo-
genic and contribute to the risk of SCD.
Large, randomized clinical trials have shown that angio-
tensin converting enzyme (ACE) inhibitors improve sur-
vival in postmyocardial infarction patients (5–10). A num-
ber of the actions of the ACE inhibitors are likely to be
important in this mortality reduction. These agents atten-
uate left ventricular dilatation and thereby result in less
ventricular enlargement (11). Further, two large studies
with long term follow-up, the Survival and Left Ventricular
Enlargement (SAVE) Trial (5) and the Studies of Left
Ventricular Dysfunction (SOLVD) (12), have demon-
strated a reduction in the risk of subsequent myocardial
infarction in patients treated with ACE inhibitors. Since the
majority of patients who die suddenly have fresh coronary
thrombus, the reduction in risk of myocardial infarction
may be important in reducing the risk of SCD. Also, the
ACE inhibitors have been shown to be sympatholytic (13)
and to preserve plasma potassium, which reduces the like-
From *the Clinical Trials Group and †the Office of Biostatistics Research, National
Heart, Lung and Blood Institute, Bethesda, Maryland and #the Cardiovascular
Division, Brigham and Women’s Hospital, Harvard Medical School, Boston,
Massachusetts. Dr. Exner is a Clinician Scientist (Phase I) of the Medical Research
Council of Canada and a Research Fellow of the Alberta Heritage Foundation for
Medical Research.
Manuscript received February 18, 1998; revised manuscript received October 22,
1998, accepted November 16, 1998.
Journal of the American College of Cardiology Vol. 33, No. 3, 1999
© 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00
Published by Elsevier Science Inc. PII S0735-1097(98)00609-3
lihood of malignant ventricular arrhythmias. These benefi-
cial effects of ACE inhibition are believed to be helpful in
preventing SCD. Since SCD is only a component of
cardiovascular mortality, no single trial could be adequately
powered to address the mechanistic question of the thera-
peutic effect of ACE inhibitor therapy on this mode of
death.
METHODS
Data identification. We attempted to identify all random-
ized trials of ACE inhibitors in patients following acute
myocardial infarction published between January, 1978 and
August, 1997. We searched for studies in the MEDLINE
database (National Library of Medicine). Study abstracts
were reviewed and those that could not be excluded, based
on criteria listed below, were reviewed in full. Reference lists
of these papers and of relevant review articles were scruti-
nized for sources of additional published data.
Studies were included if they met the following criteria:
1) randomized comparison of an ACE inhibitor to placebo
in patients with a history of myocardial infarction within the
prior 14 days, 2) study duration $6 weeks and blinded
follow-up for $6 weeks and 3) total mortality, cardiovas-
cular mortality and SCD mortality were reported or could
be obtained from the investigators. These criteria were
chosen to reduce the influence of deaths during the periin-
farction period in order to study the effect of ACE inhibitor
on SCD unrelated to the index infarction and to reduce the
potential for bias associated with not using a placebo
control.
Definitions of sudden cardiac death. Deaths were classi-
fied as “sudden cardiac” from information in the published
manuscripts (11 trials) or by contacting the authors (four
trials). Specifically, five of the 15 trials utilized an endpoints
committee to validate “sudden deaths” using a prespecified
definition of unexpected death within one hour of symptom
onset (5–7,14–16). These 5 trials contributed 867 of the
900 (96%) sudden deaths. A prespecified definition of
sudden death was used in this paper to label the causes of
death in seven other trials. The definition utilized was “sudden
unexpected collapse without documentation of arrhythmia or
collapse due to intractable ventricular tachycardia/fibrillation.”
Deaths were classified using information available in the
published manuscript in three trials (17–19) and by obtain-
ing this information directly from the authors in four
additional trials (20–23). These seven trials contributed 20
(2.2%) additional sudden cardiac deaths. In two trials,
deaths were labelled as sudden cardiac without further
description (24–25). These two trials contributed 13 (1.5%)
deaths. In the remaining trial no deaths were reported (26).
Statistical methods. Separate analyses were performed for
SCD, all cardiac deaths and total mortality. Observations
were pooled using a weighted average, with weights in-
versely proportional to the variance of the effects. To
calculate the odds ratios a constant of 0.5 was added to all
counts to improve the estimation of the odds ratios and their
variances (27). The summary odds ratios for the three
analyses were calculated both for the DerSimonian and
Laird random effects methods and for the Mantel-Hanszel
fixed effects methods (28). The random effects method was
chosen, a priori, for the primary analysis. Cochran’s test was
used to examine the homogeneity of the treatment effects
across trials overall with respect to each endpoint and
among the subsets of trials with follow-up of ,6 months
duration and those with $6 months duration (28). Since
three trials had a follow up of exactly 6 months, the
subgroups with #6 months duration and .6 months
duration were also considered. A sensitivity analysis was
performed in which each trial was deleted in turn and the
metaanalysis recomputed. The purpose of this analysis was
to make certain that the overall results did not depend solely
on a single, influential trial. Individual and overall random
effects odds ratios (OR) with corresponding 95% confidence
intervals (CI) are reported. Furthermore, logistic regression
was used to evaluate the influence of the baseline charac-
teristics of the individual trials (Table 1) on the observed
effect of ACE inhibitors on SCD, and simple linear
regression was used to assess the relationship of trial
duration and the effect of ACE inhibitors on SCD. These
analyses were performed using SAS 6.10 and Stata Release
5.0 statistical packages.
RESULTS
Pooling of trials. We identified 374 articles whose ab-
stracts were retrieved and carefully reviewed for possible
inclusion. Abstracts were examined and studies eliminated if
they did not meet the inclusion criteria. Thirty studies that
remained candidates for inclusion after examination of their
abstracts were retrieved in full. Of these studies, eight were
excluded because the active therapy or follow-up period was
less than 6 weeks (8,10,29–34), one due to initiation of
therapy more than 14 days after myocardial infarction (35),
one because not all of the patients had suffered a myocardial
infarction (36), one because it was a preliminary report of
data subsequently reported and included in the present
analysis (37), and four due to the absence of a placebo
control group (9,38–40). The remaining 15 trials used in
this analysis (5–7,14–25) included a total of 15,104 patients
(7,658 randomized to active therapy and 7,446 to placebo).
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AAD 5 antiarrhythmic drug
CI 5 confidence interval
MI 5 myocardial infarction
OR 5 odds ratio
SCD 5 sudden cardiac death
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Baseline characteristics of the patients in each of the 15
trials are shown in Table 1.
Mortality results (Table 2 and Fig. 1). There were 2,356
deaths, of which 302 (13%) were noncardiovascular and
2,054 (87%) were cardiovascular. Of the 2,054 cardiovascu-
lar deaths, 900 (44% of cardiovascular deaths and 38% of
total deaths) were considered to be sudden by the investi-
gators. Of the 7,658 ACE inhibitor assigned patients, there
were 1,105 (14.4%) deaths, and of the 7,446 patients in the
placebo group, there were 1,251 (16.8%) deaths (OR 5
0.83; 95% CI 0.71–0.97). Cardiovascular death occurred in
958 (12.5%) of active treatment patients and 1,096 (14.7%)
of placebo treated patients (OR 5 0.82; 95% CI 0.69–
0.97). SCD occurred in 407 (5.3%) ACE inhibitor treated
patients and 493 (6.6%) of placebo patients (OR 5 0.80;
95% CI 0.70–0.92). In contrast, noncardiovascular death
occurred in 147 (1.9%) of treated and 155 (2.1%) of placebo
patients (OR 5 0.87; 95% CI 0.69–1.09).
Impact of trial duration and baseline covariates. Study
duration was not correlated with the observed odds ratios
for SCD (Fig. 1). This was evidenced by the homogeneity
of the results in both trials ,6 months and those $6
months in duration (p . 0.79). While trials ,6 months in
duration were homogeneous for cardiovascular and total
mortality (p . 0.30), trials $6 months were not homoge-
neous for these endpoints (p , 0.01). Furthermore, trials
#6 months and .6 months in duration were homogeneous
with respect to all three endpoints (p . 0.41). Finally, study
duration was not significantly linearly correlated with the
odds ratio for SCD in each trial (p 5 0.60).
A logistic regression model with dichotomous variables
for each trial and treatment group yielded a similar highly
significant effect of ACE inhibitors on reducing SCD
(OR 5 0.80; 95% CI 0.70–0.92; p # 0.001). While the use
of aspirin, beta-adrenergic blocking agents, calcium channel
blockers and thrombolytic therapy varied among the trials,
as did the prevalence of diabetes and hypertension (Table 1),
these variables were not significant when added to the
logistic regression model (p . 0.28) and had only a small
effect on the estimated treatment effect.
Sensitivity analyses. We did not include the GISSI-3 trial
(9) in the primary analysis because it was not placebo-
controlled and lisinopril was only prescribed for 42 days.
However, we were able to obtain the number of SCD,
cardiac deaths and total deaths during the initial 42 days
(personal communication: Aldo Maggioni). When the
GISSI-3 results were considered along with the 15 trials
included in the primary analysis, a similar protective effect of
ACE inhibitors was observed on SCD (OR 5 0.81; 95% CI
0.72–0.89; p , 0.001).
The ISIS-4 trial also was not included in the primary
analysis since information on the mode of death was not
collected and the trial duration was only 35 days (8).
However, a similar impact on overall mortality was observed
(OR 5 0.88; 95% CI 0.80–0.96; p 5 0.005) when the
results of ISIS-4 were considered along with the original set
of trials and GISSI-3.
A further sensitivity analysis removed each of the 15 trials
in turn and recomputed the odds ratios. Very similar point
estimates resulted. In particular, the results were unchanged
even with the omission of CONSENSUS 2, the largest
trial. Overall, the trials were homogeneous with respect to
SCD (p 5 0.90) but not with respect to cardiovascular
mortality (p 5 0.05). For mortality, lack of homogeneity
Table 1. Baseline Characteristics
Study
(by duration) Year Drug Follow-up Age Male EF
b-
blocker CCB Aspirin HTN DM Lytic
(45–179 days)
Mortarino26 1990 captopril 2 months 57 76% 0.36 0% 0% 0% — — —
Oldroyd24 1991 captopril 2 months 60 83% 0.36 — — — 25% 7% 0%
Nabel17 1991 captopril 3 months 54 82% 0.50 34% 29% — — — 100%
Sharpe25 1991 captopril 3 months 58 83% 0.41 21% 19% — 32% — 72%
SMILE14 1995 zofenopril 6 weeks 64 73% — 20% 10% 54% 40% 21% 0%
EDI20 1997 enalapril 6 weeks 62 87% 0.33 49% — 96% 31% — 69%
ECCE18 1997 enalapril 3 months 62 80% 0.46 52% 13% 54% 16% 10% 63%
($180 days)
CONSENSUS 215 1992 enalapril 6 months 66 73% — 67% 23% — — 11% 56%
SAVE 215 1992 captopril 42 months 59 83% 0.31 36% 42% 59% 43% 22% 33%
AIRE7 1993 ramipril 15 months 65 74% — 22% 16% 78% 28% 12% 58%
PRACTICAL19 1994 enalapril/captopril 12 months 64 73% 0.45 17% 17% — — — 72%
Søgaard21 1994 captopril 6 months 59 91% 0.40 76% — 100% 17% 12% 81%
CATS22 1994 captopril 12 months 60 75% 0.54 13% 0% 32% 22% 9% 100%
TRACE6 1995 trandolapril 24–42 months 67 72% # 0.35 16% 28% 91% 23% 14% 45%
EDEN23 1997 enalapril 6 months 56 91% 0.48 28% 6% 84% — — 59%
CCB 5 calcium channel blocker; DM 5 diabetes mellitus; EF 5 mean ejection fraction; HTN 5 hypertension; Lytic 5 thrombolytic therapy at the time of myocardial infarction.
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was of borderline significance (p 5 0.09). These results
justify our a priori choice of the random effects method of
estimation.
DISCUSSION
Study results. The present study confirms individual re-
ports showing that treatment with ACE inhibitors reduce
overall mortality in patients following acute myocardial
infarction. Total mortality is the most definitive endpoint in
judging the usefulness of any therapy. The combined studies
in this metaanalysis also demonstrated that the reduction in
total mortality was mostly the consequence of a reduction in
cardiovascular mortality. Further, the present analysis sug-
gests that ACE inhibitors reduce the risk of SCD by about
20% in postmyocardial infarction patients, contributing
substantially to the reduction of cardiovascular mortality
and, hence, to the reduction of total mortality.
Possible mechanisms of SCD reduction. The mecha-
nisms by which ACE inhibitors prevent SCD have not been
fully delineated. However, there are several mechanisms
that have been postulated. ACE inhibitors have significant
sympatholytic activity (41). Sympathetic activation increases
the risk of ventricular tachyarrhythmias. Treatment with an
ACE inhibitor may reduce circulating norepinephrine as
well as of angiotensin II, which is a facilitator of adrenergic
neurotransmission (41). ACE inhibitors may also increase
prostacyclin synthesis which reduces local norepinephrine
release (42). Improvement in hemodynamic state may also
result in sympathetic withdrawal, reducing sympathetically
mediated vasoconstriction. As well, the use of ACE inhib-
itors also provides some protection against potassium de-
pletion since it may offset the potential adverse effects of
diuretics. In patients with high blood pressure, diuretics
may increase mortality (45). Since many postmyocardial
Figure 1. Odds ratios (OR) and their 95% confidence intervals
(CI) for the endpoint of sudden cardiac death (SCD) in each of
the 15 individual trials. The overall OR for SCD in patients
randomized to ACE inhibitor therapy was 0.80 (95% CI 0.70 to
0.92). Results are shown on a log scale with box width proportional
to the sample size.
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infarction patients are on diuretics, the potassium sparing
effects of the ACE inhibitors may reduce the risk of fatal
arrhythmias. Finally, baroreflex sensitivity is increased by
ACE inhibition and this may be an important mechanism
of reducing sympathetic, and enhancing of vagal tone,
potentially reducing SCD (41,43,44).
Effect of ACE inhibitors on remodeling. Attenuation of
the remodeling process that follows myocardial infarction is
a third way in which ACE inhibitors may be beneficial in
reducing the risk of SCD. Remodeling is associated with
changes in the function and distribution of cardiac myocytes
(46) and in the cardiac interstitium (47). These changes lead
to dilatation (3), hypertrophy (48) and to reduced contrac-
tility (49) all of which are associated with a poor prognosis
(49). Although generally related to alteration in left ventric-
ular function, the resulting abnormalities in the structure
and function of the myocardium may contribute to the
generation of ventricular arrhythmias. The ACE inhibitors
have been shown to attenuate ventricular remodeling (50).
Since a reduction in cardiac dilatation may lead to a
reduction in ventricular arrhythmias (51), ACE inhibitor
therapy may have a role in reducing fatal arrhythmias.
Indeed, Søgaard et al. reported less ventricular ectopy in
ACE inhibitor treated patients following myocardial infarc-
tion (52). In a Holter monitor substudy of SAVE patients,
fewer premature ventricular contractions were reported in
the ACE inhibitor treated patients (53). In an animal model
of chronic myocardial infarction, ACE inhibitor therapy
resulted in a reduction of electrophysiologically inducible
ventricular arrhythmias (54). Although not directly antiar-
rhythmic, the reduction in propensity to ventricular arrhyth-
mias afforded by the ACE inhibitors is likely related to
attenuation of the remodeling process, reduction in potas-
sium depletion, its sympatholytic properties and other
properties that are not well understood.
Effect of ACE inhibitors on recurrent myocardial infarc-
tion. Sudden cardiac death may also result from the elec-
trical instability due to coronary occlusion and resultant
myocardial infarctions. An autopsy study suggested that
about 75% of patients who die suddenly have new thrombus
in a coronary artery (55) which suggests a causal role in
arrhythmia generation. Chronic ACE inhibitor therapy in
patients with left ventricular dysfunction has been shown to
reduce the incidence of myocardial infarction in both the
SAVE and SOLVD studies (5,12). This prevention of
myocardial infarction may be another mechanism by which
the ACE inhibitors can reduce SCD. There are mecha-
nisms of SCD other than ventricular arrhythmias, including
ventricular rupture. Treatment with ACE inhibitors favor-
ably impacts the ventricular remodeling process (56) and
may reduce the risk of ventricular rupture (57).
Limitations. A potential limitation of this study, common
to all metaanalyses, is the possibility of publication bias.
Such bias is less likely to have influenced this metaanalysis,
because SCD was not the primary endpoint of any of the
studies. Hence, the fact that a study was negative with
respect to reducing SCD is unlikely to have decreased the
enthusiasm of authors or reviewers for the study. Also, the
clinical trial has become the standard for determining the
usefulness of therapeutic interventions. As a result, a ran-
domized trial that bears on the usefulness of a class of drugs
as important as ACE inhibitors is likely to be submitted for
publication and published, whether positive or negative.
Conclusions. This analysis is consistent with prior reports
showing that ACE inhibitor treatment reduces total mor-
tality in postmyocardial infarction patients by reducing
cardiovascular mortality. Furthermore, it suggests that the
estimated 20% reduction in the odds of SCD by the ACE
inhibitors is a significant component of the reduction of
cardiovascular death.
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